What Is FGF15? Definition and What Research Reports

Plain definition

FGF15 is an endocrine fibroblast growth factor — a signalling protein, not a small synthetic peptide — that is expressed chiefly by enterocytes of the distal small intestine (ileum) in rodents. Its expression is switched on when bile acids returning from the gut activate the nuclear bile acid receptor FXR (farnesoid X receptor); the protein then travels through the portal circulation to the liver, where it participates in feedback control of bile acid synthesis. Because this route runs from intestine to liver, the literature routinely describes FGF15 as a gut–liver crosstalk hormone and groups it with its human counterpart under the shorthand "FGF15/19". A 2022 review of the bile acid–FXR–FGF15/19 signalling axis set out the molecular basis of this pathway, including receptor complex formation and downstream hepatic signalling (PMID 35682726).

What class of molecule is it?

FGF15 belongs to the endocrine subfamily of fibroblast growth factors. Unlike classical paracrine FGFs, endocrine FGFs have low affinity for heparan sulfate, which allows them to leave the tissue of origin and circulate. Their receptor engagement depends on a co-receptor of the Klotho family — β-Klotho for the FGF15/19 subfamily — paired with an FGF receptor on the target cell. The 2022 review described this receptor architecture and the downstream events that follow ligand binding in hepatocytes as the structural core of the axis (PMID 35682726).

FGF15 versus FGF19

The two names are frequently written together because they refer to species counterparts rather than to two interchangeable molecules. Papers using mouse or rat models generally write "FGF15"; papers describing human tissue, human cells or human sequence generally write "FGF19"; reviews spanning both write "FGF15/19". Sequence identity between the two is modest, so findings in one species are not automatically transferable to the other — a caveat worth holding in mind when reading any summary that blurs the two terms.

How the term is used in peptide and protein research

In research writing, "FGF15" almost always functions as a readout or a pathway node rather than as a test article. Investigators typically measure ileal Fgf15 messenger RNA or circulating protein to infer whether intestinal FXR signalling has been engaged, then look downstream at hepatic bile acid synthesis genes. Occasionally the protein itself is administered in an animal model to ask what the signal does when supplied exogenously. Both usages appear in the verified literature summarised below. The term also appears in discussions of the microbiome, because gut bacteria modify bile acids and therefore influence how strongly ileal FXR — and thus FGF15 — is activated.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment. Nothing here describes a protocol, and no human use of FGF15 is described in the studies cited.

What the published literature reports

Bile acid and lipid homeostasis

The gut–liver feedback role is the best-characterised function. A 2022 FASEB Journal study reported that the transcription factor TCF7L2 transcriptionally regulates Fgf15 and that this regulation contributed to maintaining bile acid and lipid homeostasis through gut–liver crosstalk (PMID 35133032). That work placed FGF15 downstream of an additional transcriptional input beyond FXR alone, which researchers used to argue that intestinal transcriptional programmes help set the strength of the hepatic feedback signal. The broader 2022 review framed the same axis mechanistically, describing how bile acid ligands, FXR activation and FGF15/19 output are linked in sequence (PMID 35682726).

Cholestasis models and the microbiome

A 2023 study in Nutrients reported that the probiotic Pediococcus pentosaceus Li05 improved cholestasis in an animal model, and the authors attributed the improvement to the FXR–SHP and FXR–FGF15 pathways (PMID 38068723). In that study FGF15 was measured as part of the mechanism rather than given as a treatment, which is the typical pattern for microbiome-facing work on this axis.

Inflammation and immune modulation

A 2022 paper in the Journal of Inflammation Research reported that FGF15 protected septic mice, with the authors describing inhibition of inflammation and modulation of regulatory T cell (Treg) responses as the mechanisms observed (PMID 36386580). This is one of the few entries in the verified set where FGF15 was studied as an intervention in animals rather than purely as a biomarker of FXR activation.

Skeletal muscle in aged animals

A 2022 report in Mechanisms of Ageing and Development found that activation of ileal FXR–FGF15/19 signalling improved skeletal muscle loss in aged mice (PMID 35026209). The study addressed the gut-derived signal in the context of age-related muscle decline in rodents; it did not evaluate human outcomes, and its findings have not been shown to extend beyond the model used.

FGF15/19 Signalling and Liver Tumour Biology: What Studies Report

The literature on this axis is not uniformly favourable, and the counterweight is well documented. A 2018 study in the Journal of Experimental & Clinical Cancer Research reported that up-regulation of FGF15/19 signalling promoted hepatocellular carcinoma in the background of fatty liver (PMID 29973237). Researchers have therefore treated sustained elevation of this signal as a hazard to be characterised rather than a uniformly desirable outcome, and reviews of the axis discuss the tension between its metabolic signalling roles and its mitogenic potential in liver tissue (PMID 35682726). Any reading of the beneficial-sounding animal results above is incomplete without this finding alongside it.

What the cited literature does not establish

• No human dosing data. None of the verified studies described administration of FGF15 to people, and no dose, route or duration for human use appears in them.
• Species gap. FGF15 is the rodent molecule; human work uses FGF19. Findings in septic mice (PMID 36386580) or aged mice (PMID 35026209) were reported in those models only.
• Mechanism versus outcome. In the cholestasis work, FGF15 was part of the proposed mechanism for a probiotic effect rather than the agent administered (PMID 38068723).
• Directionality matters. The same axis has been reported as protective in some models and as tumour-promoting in a fatty-liver background (PMID 29973237).

Quick reference

References

• Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis (International Journal of Molecular Sciences, 2022)
• Probiotic Pediococcus pentosaceus Li05 Improves Cholestasis through the FXR-SHP and FXR-FGF15 Pathways (Nutrients, 2023)
• FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses (Journal of Inflammation Research, 2022)
• Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver (Journal of Experimental & Clinical Cancer Research, 2018)
• TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk (FASEB Journal, 2022)
• Ileal FXR-FGF15/19 signaling activation improves skeletal muscle loss in aged mice (Mechanisms of Ageing and Development, 2022)